Site Search

1. 51.
   amp24/assets/TechPosterAwardWinners.pdf?pass=59

   Overall, the concordance of reportable SNVs and indels with orthogonal methods was 99.8% (586/587) and 100% (128/128), ... included KMT2D (7%), TP53 (6%), BCL2 (5%), and TET2 (5%). The LOD was ... for variants ≥5.0% (both 99.9%) compared to variants ≥3.0% (95.0% and 96.1%, respec vely). Specificity ... to be 100% using two GIAB ... was 0.23% in FFPE and 0.24% in BM

   https://www.amp.org/amp24/assets/TechPosterAwardWinners.pdf?pass=59
2. 52.
   AMP/assets/File/clinical-practice/COVID/CDRH-substitutions-diagnostic-testing...

   For more information please see the https://www.fda.gov/medical-devices/ ... more information please see the https://www.fda.gov/medical-devices ... CDC Vetted Acceptable Manufacturers (per https://www.cdc.gov/coronavirus/2019 ... Vortex Mixer Microcentrifuge Micropipettes 10% Bleach MicroAmp Optical 8-cap ... Menu Return to FDA FAQ https://www.fda.gov/medical-devices

   https://www.amp.org/AMP/assets/File/clinical-practice/COVID/CDRH-substitutions-d...
3. 53.
   Stakeholder Letter Opposing PERA September 2024.docx

   May 5, 2003), https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0. 8 https://www.fda.gov/news-events/press ... fda-roundup-december-23-2022 7 https://www.regulations.gov/comment/PTO-P ... senate.gov/imo/media/doc/Jones%20Testimony1.pdf; strategy&, PWC 2018 Global ... Association, Venture Monitor, 4Q 2018 at 19, https://files.pitchbook.com/website/files/pdf/4Q

   https://www.amp.org/AMP/assets/File/advocacy/Updated_List_Stakeholders_Opposing_...
4. 54.
   AMP/assets/File/advocacy/AMP_Position_Variant_Data_Sharing_7_29_2021.pdf?pass=26

   Med 19, 721-22 (2017) https://doi.org/10.1038/gim.2016.196 ... their minimum requirements (e.g., 95% of reportable sequencing variants with supporting ... Genet Med 23, 989-995 (2021). https://doi.org/10.1038/s41436-020-01082 ... Genet Med 21, 1476–1480 (2019). https://doi.org/10.1038/s41436-018-0370 ... Med 17, 405–423 (2015). https://doi.org/10.1038/gim.2015.30

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Position_Variant_Data_Sharing_7...
5. 55.
   AMP/assets/File/education/MIMP/CutaneousMelanomas.pdf?pass=75

   Low-CSD/SSM (>50%)1 Therapeutic Associated with sensitivity to ... D816H); and amplification High-CSD/LMM (28%)2 Acral/mucosal melanomas (15%-40%) Therapeutic Exon 11 and 13 mutations ... LMM, DM. Acral/mucosal melanomas (15%)3 Prognosis Therapeutic Associated with poor ... of tumours series, 5th ed.; vol. 12). https://publications.iarc.fr. 2. The Cancer Genome

   https://www.amp.org/AMP/assets/File/education/MIMP/CutaneousMelanomas.pdf?pass=7...
6. 56.
   AMP/assets/File/education/case-studies/1115-AMPCaseReport-LR.pdf?pass=36

   Gene Frequency CMML MDS TET2 50–60% 20–25% ASXL1 40% 14% SRSF2 46% 12.4% RUNX1 15% 9–20% SETBP1 15% 3.8–4.4% NRAS 11% 3.6% CBL 10% 2.3% KRAS 8% 0.9% ZRSR2 8% 3.1% IDH1/IDH2 1–6% 2–3.5% SF3B1 6% 14.5% (80% with RS*) tremendous enthusiasm for this drug in the clinic.7 The CBL gene encodes a ubiquitin protein ligase (E3) that down-regulates

   https://www.amp.org/AMP/assets/File/education/case-studies/1115-AMPCaseReport-LR...
7. 57.
   Microsoft Word - Perfect Storm-FINAL-CD

   Medicare costs, their findings influence as much as 60‐70% of health care decision‐making.16 ... set rates that are at least 40% and as much as 60% lower than they paid previously under ... health. It is often quoted that 70% of medical decisions are based on laboratory ... al. NEJM 2014;371:1426‐1433. 3 https://www.cgsmedicare.com/ohb/coverage/mopath/mopath

   https://www.amp.org/AMP/assets/File/position-statements/2015/PerfectStorm-FINAL-...
8. 58.
   AMP/assets/File/advocacy/AMP_IPPS_Comments_2024.pdf?pass=82

   Submitted electronically at https://www.regulations.gov Re: Proposed ... on CDC COVID-19 1 https://www.amp.org/advocacy/sars- ... federal agencies or departments. Approximately 75% of respondents reported that at the ... burden on laboratories. Sincerely, 2 https://www.amp.org/AMP/assets/File/advocacy/AMP%20Future%20Pandemic%20White%20Paper%20Response.pdf?pass=52 3

   https://www.amp.org/AMP/assets/File/advocacy/AMP_IPPS_Comments_2024.pdf?pass=82
9. 59.
   AMP/assets/File/clinical-practice/20170321-Jenningsetal2017_AMPresourceTemplate1...

   Known variants not detected (FN) FP PPA PPV SNV 5% SNV 10% indel ( 5 bp) 5% indel ( 5 bp) 10% indel (5-40 bp) 5% indel (5-40 bp) 10% Legend: This represents a sample method or ... not detected (FN) FP PPA PPV 90% NA12878/10% NA12877 SNV 5% 80% NA12878/20% NA12877 SNV 10% 90% NA12878/10% NA12877 indel ( 5 bp) 5% 80% NA12878/20% NA12877 indel ( 5 bp) 10% 90

   https://www.amp.org/AMP/assets/File/clinical-practice/20170321-Jenningsetal2017_...
10. 60.
    AMP/assets/File/position-statements/2015/AMP-CAP-Reponse-NSCLC-DL36194-DL36198...

    An oncogenic driver was found in 466 of these 733 patients (64%). Among these 733 ... 182 tumors (25%) had the KRAS ... EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more ... HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 ( 1%); MET amplification, 5 ( 1%); NRAS, 5 ( 1%); MEK1, 1 ( 1%); AKT1, 0. Results ... Cancer (Version 4.2015). https://www.nccn.org

    https://www.amp.org/AMP/assets/File/position-statements/2015/AMP-CAP-Reponse-NSC...